Payment overview · 2025
General Payments
$1,322,460.78
178 reported records · 26 companies
Healthcare provider profile · identity verified
Sahil Ashwin Parikh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1023094117
Verified facts
What the public records show
CMS Open Payments records show Sahil Ashwin Parikh, MD received $1,322,460.78 in general payments during 2025 across 178 reported records.
Shockwave Medical, Inc accounted for 95.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $1,259,829.12 | 95.3% | 60 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $18,286.12 | 1.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17,115.12 | 1.3% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $11,155.53 | 0.8% | 21 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,752.11 | 0.4% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$3,904.81 | 0.3% | 7 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $2,729.63 | 0.2% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $2,537.83 | 0.2% | 4 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $352.87 | 0.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $319.92 | 0.0% | 17 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $224.41 | 0.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $217.22 | 0.0% | 12 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $159.97 | 0.0% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $140.93 | 0.0% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $111.11 | 0.0% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $104.35 | 0.0% | 2 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $100.00 | 0.0% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $66.55 | 0.0% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $63.88 | 0.0% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.17 | 0.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.69 | 0.0% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $51.74 | 0.0% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $43.49 | 0.0% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $40.18 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.16 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.87 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $976,398.00 | 18 |
| Grant | $202,500.00 | 3 |
| Consulting Fee | $116,862.50 | 47 |
| Travel and Lodging | $20,937.83 | 12 |
| Food and Beverage | $5,762.45 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $1,259,829.12 | 60 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $18,286.12 | 7 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $16,451.55 | 3 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $7,596.95 | 7 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $2,600.00 | 4 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $2,501.46 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $1,400.00 | 2 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $1,104.08 | 7 | 2025 |
Source payment records
|
|||||
| EVERCROSS Normalized: evercross |
Device | Medtronic, Inc. | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $700.00 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $390.69 | 4 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $352.87 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $319.92 | 17 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $207.38 | 11 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $204.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $147.91 | 9 | 2025 |
Source payment records
|
|||||
| GORE-TEX Vascular Graft Normalized: gore tex vascular graft |
Device | W. L. Gore & Associates, Inc. | $146.60 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $140.93 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $138.47 | 1 | 2025 |
Source payment records
|
|||||
| 2cm Peripheral Cutting Balloon Normalized: 2cm peripheral cutting balloon |
Device | Boston Scientific Corporation | $134.62 | 2 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $129.63 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $111.11 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $104.35 | 2 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $85.75 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $81.41 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $77.81 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $68.42 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $66.55 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $63.88 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $56.17 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $51.74 | 2 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $43.49 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $40.18 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZ GOOSE NECK Normalized: amplatz goose neck |
Device | Medtronic, Inc. | $40.17 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $36.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $9.84 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $6.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 76 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 65 | 29 |
| Losartan Potassium | Losartan Potassium | 37 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 33 | 17 |
| Eliquis | Apixaban | 29 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | 14 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,322,460.78 · 178 records | Shockwave Medical, Inc | 2cm Peripheral Cutting Balloon, ABRE, ALPHAVAC, AMPLATZ GOOSE NECK, AMVUTTRA, AngioJet Ultra 5000A, Asahi Coronary Wires, Assure WCD, Attruby, CGuard Prime Carotid Stent System, Coronary Other, ELIQUIS, ELUVIA, ESPRIT, EVERCROSS, FARAPULSE, FFRct, GORE VIABAHN Endoprosthesis, GORE-TEX Vascular Graft, General - Atherectomy, General - Therapies, General - Vascular Intervention, HAWKONE, IGT Devices Undivided, Indigo System, JARDIANCE, Kerendia, LEQVIO, LIMFLOW SYSTEM, METACROSS OTW, MYNX CONTROL VENOUS, NAVICROSS, NURTEC ODT, OPTIS, PERCLOSE PROGLIDE, Paradise Ultrasound Renal Denervation System, REPATHA, SYMPLICITY G3, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, ULTREON, VYNDAQEL | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error